mRESVIA
Moderna Wins Expanded FDA Approval for RSV Vaccine in At-Risk Younger Adults
Moderna; RSV vaccine; FDA approval; mRESVIA; at-risk adults; 18 to 59 years; expanded label; chronic health conditions
FDA Approves Moderna’s RSV Vaccine, Marking Its Second Commercial Product
Moderna, RSV Vaccine, FDA Approval, mRNA Technology, Respiratory Syncytial Virus, COVID-19, Spikevax, mRESVIA